Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
|Videos|November 13, 2021
LUGPA reimagines independent urology practice to survive pandemic and beyond
Author(s)Urology Times staff
“We found that we can move many of our staff offsite and go to remote workforce options,” says Scott Sellinger, MD.
Advertisement
At the 2021 LUGPA Annual Meeting, Scott Sellinger, MD, moderated the discussion, “Re-imagining Our Independent Urology Practices: What’s the New Normal?” The panel covered how the changes LUGPA facilitated for independent urology practices during the pandemic and what continued
Advertisement
Related to this article
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to VIR-5500 for mCRPC
2
FDA grants 510(k) clearance to OpenFlo urinary catheter
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Prostate Cancer Case Review: Biochemical Recurrence and a Rib Lesion
5